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Introduction: Breast cancer is commonly classified into intrinsic molecular subtypes. Standard gene centering is
routinely done prior to molecular subtyping, but it can produce inaccurate classifications when the distribution of
clinicopathological characteristics in the study cohort differs from that of the training cohort used to derive the
classifier.
Methods: We propose a subgroup-specific gene-centering method to perform molecular subtyping on a study
cohort that has a skewed distribution of clinicopathological characteristics relative to the training cohort. On such a
study cohort, we center each gene on a specified percentile, where the percentile is determined from a subgroup
of the training cohort with clinicopathological characteristics similar to the study cohort. We demonstrate our
method using the PAM50 classifier and its associated University of North Carolina (UNC) training cohort. We
considered study cohorts with skewed clinicopathological characteristics, including subgroups composed of a single
prototypic subtype of the UNC-PAM50 training cohort (n = 139), an external estrogen receptor (ER)-positive cohort
(n = 48) and an external triple-negative cohort (n = 77).
Results: Subgroup-specific gene centering improved prediction performance with the accuracies between 77% and
100%, compared to accuracies between 17% and 33% from standard gene centering, when applied to the prototypic
tumor subsets of the PAM50 training cohort. It reduced classification error rates on the ER-positive (11% versus 28%;
P = 0.0389), the ER-negative (5% versus 41%; P < 0.0001) and the triple-negative (11% versus 56%; P = 0.1336) subgroups
of the PAM50 training cohort. In addition, it produced higher accuracy for subtyping study cohorts composed of
varying proportions of ER-positive versus ER-negative cases. Finally, it increased the percentage of assigned luminal
subtypes on the external ER-positive cohort and basal-like subtype on the external triple-negative cohort.
Conclusions: Gene centering is often necessary to accurately apply a molecular subtype classifier. Compared with
standard gene centering, our proposed subgroup-specific gene centering produced more accurate molecular subtype
assignments in a study cohort with skewed clinicopathological characteristics relative to the training cohort.Introduction
Breast cancer is intrinsically heterogeneous. On the basis
of gene expression, breast tumors are often classified as
one of five intrinsic subtypes, luminal A (LumA), lu-
minal B (LumB), human epidermal growth factor recep-
tor 2 (HER2)-enriched, basal-like and normal-like [1-3].
The original intrinsic subtype classification was obtained
through unsupervised clustering of breast tumors based* Correspondence: sylvia.plevritis@stanford.edu
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unless otherwise stated.on the expression of the “intrinsic” gene set selected for
small intratumor variation, before and after neoadjuvant
chemotherapy, and large intertumor variation [1]. Variants
using different gene sets have emerged [2-6]. Generally,
these molecular subtypes are associated with distinct
biological features and clinical outcomes. They contribute
to insights into cancer initiation and progression and
could guide clinical decisions [2,3,6-8]. Hence, high
accuracy of molecular subtyping is critical.
The molecular subtype of an individual breast tumor
drawn from a study cohort is typically assigned to its
closest matching subtype expression profile. To increase
specificity, each molecular subtype is defined by a cen-
troid based on gene expression values in the traininghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that has the highest correlation between the subtype’s
centroid and the study tumor’s corresponding gene ex-
pression pattern [2-4,6]. Gene expression levels vary
greatly because of technical biases, so it is necessary to
center the gene expression values in the study cohort
prior to subtyping [9]. Standard gene centering is typic-
ally done by subtracting the median or mean expression
per probe or gene across the study cohort. However,
standard gene centering introduces errors in molecular
subtype classifications when the clinicopathological dis-
tributions of the study cohort do not match those of the
training cohort used to derive the molecular subtype
classifier.
Training cohorts used to develop the subtype expression
signature are often intended to represent the general pa-
tient population [1-3,6]. For PAM50 [6] classifiers, the ori-
ginal training cohort, referred to as the University of
North Carolina (UNC) dataset, is regarded as capturing
the major breast cancer types in the general patient popu-
lation in their relative proportions. When using the intrin-
sic subtype classifier, the clinicopathological distribution
of breast cancer of the study cohort should be similar to
that of the training cohort [9]. For study and training co-
horts with similar clinicopathological distributions, sys-
tematic differences in gene expression are assumed to be
due to technical biases; after standard gene centering to
remove these technical biases, the cohorts are considered
comparable. In the case of the PAM50 signature, the UNC
dataset was centered probe-wise prior to establishment of
the centroids for the subtypes.Figure 1 Effect of estrogen receptor distribution on molecular subtyp
PAM50 training cohort. Only samples with available prototypic tumor subty
each horizontal strip, the vertical bands represent individual patients and a
considered the UNC cohort, where there was a balanced ER-positive to ER-ne
(64/118)—represented by the shaded pie chart labeled “UNC cohort.” In the f
depicted as dark vs. light gray, representing ER-positive vs. ER-negative cases,
the original subtype assignments on the UNC cohort are shown. Next, we con
sampling ER-positive and ER-negative cases disproportionally, with 15% ER-po
chart labeled “UNC subset.” In the third strip, labeled “Standard gene centerin
UNC subset, where ER is disproportionally distributed, are shown. The misclas
second strip. In the bottom strip, labeled “Subgroup-specific gene centering,”
the subset of the UNC cohort, where ER is disproportionally distributed, are sh
similar to the actual classification, shown in the first 75 cases of the second str
factor receptor 2; LumA, Luminal A; LumB, Luminal B.Although standard gene centering is commonly ap-
plied prior to molecular subtyping, it produces inaccurate
molecular subtype classifications when the study and
training cohorts differ in their clinicopathological compos-
ition. In particular, if the training cohort is intended to
capture the heterogeneity of the general patient popula-
tion, standard gene centering will not produce molecular
subtype classifications on a study cohort with more nar-
rowly defined clinicopathological characteristics relative to
the general population, such as a study cohort of only ER-
positive cases. More generally, if one were subtyping using
standard gene centering and evaluating the assignments
by ER status, the assignment to each ER-positive case
would depend on how many ER-negative cases are in the
study cohort. Similarly, the assignment to the ER-negative
cases would depend on how many ER-positive are in the
study cohort (Figure 1). The most accurate assignment
would occur only when the proportion of ER-positive to
ER-negative cases was similar to that of the training co-
hort; otherwise, errors would occur, as we demonstrate in
this article.
A few approaches have been proposed to remedy the
problem of applying standard gene centering when the
study and training cohorts differ in terms of clinicopath-
ological distribution. One can augment the study cohort
with additional samples to form a new study cohort that
better matches the heterogeneity of the training cohort.
However, this approach assumes the availability of add-
itional samples profiled on the same platform. Alterna-
tively, one might consider subsetting or resampling the
study cohort to match the training cohort in terms ofe assignments. The University of North Carolina (UNC) cohort is the
pes and available estrogen receptor (ER) status are shown (n = 118). In
re arranged in the same sequence for each horizontal band. First, we
gative distribution—46% ER-positive (54/118) and 54% ER-negative
irst strip at the top, labeled “ER status”, the ER status on the UNC cohort is
respectively. In the second strip, labeled “Original subtype assignment,”
sidered a subset of the UNC cohort (n = 75), which we created by
sitive (11/75) and 85% ER-negative (64/75), as represented by the pie
g,” assigned subtypes by standard gene centering on the subset of the
sification rate is 33.3% (25/75) compared with the first 75 bands in the
assigned subtypes by the proposed subgroup-specific gene centering on
own. The misclassification rate is 5.3% (4/75). Here the classification is
ip, labeled “Original subtype assignment.” Her2, Human epidermal growth
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setting makes inefficient use of the study data by removing
samples, whereas resampling introduces randomness
through the sampling scheme. Moreover, both of these ap-
proaches assume that the study cohort contains some
fraction of all the subgroups in the training cohort, which
would not be the case if the study cohort were only ER-
positive patients, for example. Model-based methods (for
example, distance-weighted discrimination [12]) have been
proposed to remove technical bias while keeping biologic-
ally relevant signals; for these approaches, one should be
cautious about the relevance of the underlying modeling
assumptions.
To perform subtype classification on a study cohort
whose clinicopathological composition differs from the
training cohort, we propose subgroup-specific gene center-
ing that corrects for these differences. Our method is a
probe-wise, platform-independent, model-free strategy for
subtype classification that does not rely on altering the
study cohort by augmenting, removing or resampling it.
Methods
For illustration purposes, we compare our subgroup-
specific gene centering with standard gene centering
using the PAM50 classifier. We refer to the baseline ex-
pression of a gene as the value against which that gene is
centered. For standard gene centering, all probes are
median-centered prior to classification by PAM50. An-
other subtyping method may define the baseline value
differently (for example, it may be the mean); regardless,
our approach, as presented below, would still apply.
Formulation of subgroup-specific gene centering
We propose a subgroup-specific centering method, illus-
trated in Figure 2, to replace standard gene centering
when subtyping a study cohort that differs from the
training cohort in terms of its clinicopathological distri-
bution. The steps illustrated in Figure 2 are performed
on each gene of the gene expression signature, which is
the PAM50 signature in this case.
In the training cohort, we compute the expression base-
line, μgene, of each gene. In PAM50, this is the median gene
expression across the cohort. In standard gene centering,
μgene is subtracted from the expression value of that gene.
In our approach, prior to classification, we sample a
subgroup of the training cohort with a clinicopathologi-
cal distribution similar to that of the study cohort. For
this subgroup, we find the expression value at the per-
centile Qgene that corresponds to the percentile of the
baseline expression μgene of the entire training cohort. In
other words, we estimate where the baseline expression
μgene of the entire training cohort lies within the study
cohort. We then assign the baseline expression of each
gene at the Qgene percentile and center the gene expressionby subtracting the value at this percentile. Additional file 1:
Table S6 lists baseline values precomputed for common
breast cancer subgroups, specifically ER-positive, ER-
negative and triple-negative cases.
For example, consider the gene ESR1, whose median
expression value is 1.68 in the UNC training cohort and
lies at 20th percentile for the ER-positive subgroup of
the training cohort. If one were molecularly subtyping
the ER-positive-only study cohort published by Borgan
et al. [13], the expression value of ESR1 would be ad-
justed by subtracting its median value of 3.34 using
standard gene centering. Using our approach, the ex-
pression of ESR1 is centered on the value corresponding
to the 20th percentile for the study cohort, which is 1.3
(see Additional file 2: Figure S1). Below we show that
our approach produces fewer errors for molecular sub-
type classification.
If the study cohort were a mixture of several sub-
groups (for example, a mixture of 15% ER-positive and
85% ER-negative samples), the gene-specific percentiles
could be computed based on a sampling of the training
cohort with a similar mixture.
Subgroup-specific gene centering was implemented in
R (version 3.0.0) [14]. Data and code were deposited in
the Stanford Center for Cancer Systems Biology Data
Integration Core database [15]. The supplementary files
provide statistical and implementation details.
Evaluation of subgroup-specific gene centering and
associated datasets
We demonstrate the improved performance of subgroup-
specific versus standard gene centering on two types of
study cohorts. First, we considered study cohorts derived
from the UNC dataset, where the “true” (or prototypic)
subtypes for the tumors were known but blinded from our
classifier. Second, we considered two external study co-
horts: namely, cohorts independent of the UNC dataset
used to develop the PAM50 classifier. One external cohort
was composed of only ER-positive tumors and the other
of only triple-negative breast cancer (TNBC). All the data
analyzed in this study were previously published. Ethical
approval was not required because no human breast tissue
was acquired for this study.
Evaluation of subgroup-specific strategy on study cohorts
derived from the PAM50 training cohort
For the purposes of quantifying the accuracy of subgroup-
specific versus standard gene centering, we derived study
cohorts from subgroups of the UNC dataset [GEO:
GSE10886] (see also Additional file 3: Supplementary
methods). We considered the five UNC prototypic tumor
subgroups: the prototypic LumA set, the prototypic LumB
set, the prototypic HER2-enriched set, the prototypic
basal-like set and the prototypic normal-like set. These
Figure 2 Overview of subgroup-specific gene-centering algorithm. (a) Distribution of gene expression for a representative gene from the
entire University of North Carolina (UNC) training cohort, with the global mean represented by the gray vertical dotted line. (b) The gene
expression baseline is approximated by the global mean (gray dotted line) shown on the global distribution, represented as a mixture of
estrogen receptor (ER)-positive cases (shown in pink) and ER-negative cases (shown in green). (c) and (d) The global median is located on
different percentiles for the ER-positive and ER-negative cases, and each differs with respect to each subgroup mean. (e) The distribution of gene
expression for the same gene in a study cohort composed of only ER-positive cases. The baseline value for subgroup-specific gene centering is
estimated at the corresponding percentile of the ER-positive subgroup in the study cohort and compared with the median value, represented by
the red vertical dotted line. The difference between these values is the error introduced by standard gene centering. (f) Similar to (e), but for the
ER-negative subgroup.
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troids) for each of the molecular subtypes. In addition, we
considered three clinically defined tumor subgroups of the
UNC dataset, namely: ER-positive, ER-negative and triple-
negative subsets. Here the UNC dataset was regarded as a
representative cohort of breast cancer, and prototypic la-
bels of the UNC samples were considered the true mo-
lecular subtypes when computing the subtyping accuracy.
To assess classification accuracy, the prototypic subtypes
for the tumors were known but blinded from the classifier.
The classification accuracy was calculated as the percent-
age of samples with predicted subtype matching their
prototypic labels, and the misclassification percentage was
the error rate.Evaluation of subgroup-specific strategy on external study
cohorts
Triple-negative cohort The TNBC dataset (n = 77) is a
subset of The Cancer Genome Atlas (TCGA) breast data
[11] with negative immunohistochemical expression for
ER, progesterone receptor and HER2. This TCGA level
3 dataset, its clinical annotation and the published mo-
lecular subtype calls were obtained through the TCGA
website [16].
Estrogen receptor-positive cohort The Trondheim set
(n = 48) is a published dataset of ER-positive breast tumors
from Trondheim, Norway [13]. The article by Borgan
et al. [13] includes information for data preprocessing
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study provided the data (see Acknowledgements) and
stated that ethical approval was granted by the regional
committee for medical and health research ethics (REC
Central, Norway). The approval numbers are 4.2006.216
(before 2010) and 2010/331 (after 2010).
On these external study cohorts, associations between
molecular subtypes with known clinicopathological fea-
tures were used to assess the subtype assignments. En-
richment of luminal and the basal-like subtypes were
assumed for the external ER-positive cohort (Trondheim
set) and the TNBC dataset, respectively. In addition, for
the external TNBC dataset, subgroup-specific and stand-
ard centering were benchmarked against the published
PAM50 subtype classifications, which were generated
using the full TCGA dataset.
Results
Evaluation of subgroup-specific strategy on study cohorts
derived from the UNC dataset
Prototypic subgroups from the UNC dataset
We evaluated subgroup-specific versus standard gene cen-
tering for predicting the intrinsic subtypes on subgroups
composed of single intrinsic subtypes from the UNC data-
set (Table 1 and Figure 3). We assessed a molecular classi-
fication as correct if it matched the prototypic subtypes.
With standard gene centering, the prediction accuracy
range was 17% to 33% across the five intrinsic subtypes.
Subgroup-specific gene centering produced accuracies in
the range from 77.1% to 100%, with 98.2% (56/57) for
basal-like, 77.1% (27/35) for HER2-enriched, 91.3% (21/23)
for LumA, 100% for LumB (12/12) and 100% (12/12) for
normal-like prototypic tumors.
Clinically defined subgroups from the UNC dataset
Next, we evaluated the subtyping accuracy on the ER-
positive, ER-negative and triple-negative subgroups ofTable 1 Comparison of gene centering with a subgroup-speci
Pre
Dataset Subgroup Gene-centering method Bas
Prototypic basal Basal-like Standard 12
(n = 57) Subgroup-specific 56
Prototypic HER2 Her2-enriched Standard 8 (2
(n = 35) Subgroup-specific 2 (5
Prototypic LumA Luminal A Standard 7 (3
(n = 23) Subgroup-specific 0 (0
Prototypic LumB Luminal B Standard 2 (1
(n = 12) Subgroup-specific 0 (0
Prototypic normal Normal-like Standard 2 (1
(n = 12) Subgroup-specific 0 (0
aHER2, Human epidermal growth factor receptor 2; LumA, Luminal A; LumB, Luminathe UNC dataset. On the ER-positive subgroup (Additional
file 1: Table S2), the error rate was 11% (6/54) versus
27.8% (15/54) error by subgroup-specific versus standard
gene centering, respectively (P = 0.0389 by McNemar test).
Our method mostly misclassified prototypical HER2-
enriched samples. Four prototypic HER2-enriched sam-
ples were classified as LumB, and one was classified as
basal-like. One prototypic LumA tumor was misclassified
as LumB. On the ER-negative subgroup (Additional file 1:
Table S3), our method versus the standard method pro-
duced an error rate of 5% (3/64) versus 41% (26/64),
respectively (P < 0.0001 by McNemar test). With our
method, only two prototypic HER2-enriched tumors were
assigned to LumB and LumA, respectively, and one proto-
typic basal-like tumor was misclassified as normal-like.
On the UNC triple-negative subgroup (Additional file 1:
Table S4), our method produced an 11% (1/9) error rate,
with one prototypic basal-like tumor incorrectly classified
into normal-like, compared with a 56% (5/9) error rate by
standard gene centering (P = 0.1336 by McNemar test;
note that the small sample size, n = 9, is likely insufficient
to detect a statistically significant difference). In supple-
mentary work, we assessed the subtyping accuracy using
our subgroup-specific strategy as a function of the sample
size of the prototypic subgroup, shown for the basal sub-
group in Additional file 4: Figure S3.
Mixture of ER-positive and ER-negative subgroups from the
UNC dataset
We assessed the subtype prediction performance on sub-
groups constructed with a varying percentage of ER-
positive samples, gradually increasing from 0% to 100% in
10% increments (Figure 4). To construct these subgroups,
samples were randomly drawn from the UNC dataset to
achieve the specified ER distributions. Subgroup-specific
gene centering was done after sampling a subgroup of the
UNC set with a similar mixture. Its error rate was lessfic strategy on the UNC prototypic tumor seta
diction (%)
al-like HER2-enriched LumA LumB Normal-like
(21.1) 8 (14) 17 (29.8) 16 (28.1) 4 (7)
(98.2) 0 (0) 0 (0) 0 (0) 1 (1.8)
2.9) 7 (20) 10 (28.6) 6 (17.1) 4 (11.4)
.7) 27 (77.1) 1 (2.9) 5 (14.3) 0 (0)
0.4) 1 (4.3) 6 (26.1) 3 (13) 6 (26.1)
) 0 (0) 21 (91.3) 1 (4.3) 1 (4.3)
6.7) 3 (25) 3 (25) 2 (16.7) 2 (16.7)
) 0 (0) 0 (0) 12 (100) 0 (0)
6.7) 2 (16.7) 2 (16.7) 2 (16.7) 4 (33.3)
) 0 (0) 0 (0) 0 (0) 12 (100)
l B; UNC, University of North Carolina.
Figure 3 Comparison of standard with subgroup-specific gene centering for predicting the individual molecular subtypes on the
prototypic datasets. Bar plot represents the counts of the predicted subtype classes in individual prototypic tumor dataset. Her2, Human
epidermal growth factor 2; LumA, Luminal A; LumB, Luminal B.
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of standard gene centering was comparable to our method
only when the proportion of ER-positive was 50% to 80%;
it produced high error rates otherwise. Applying PAM50
classification on data without any gene centering produced
the highest error rate (Figure 4), confirming the import-
ance of some form of gene centering prior to subtyping.
Application of subgroup-specific strategy on external
study cohorts composed of common clinically relevant
subgroups
In the Trondheim set (ER-positive cohort), individual
genes were centered on the ER-positive-specific percen-
tiles identified from the corresponding UNC subset
(Additional file 1: Table S1 and Additional file 2: Figure S1).
We expected the majority of the ER-positive cases would
be luminal subtypes. With standard gene centering, onlyFigure 4 Comparison of various data transformation strategies for pr
estrogen receptor proportions. Datasets were constructed with percenta
100%. The ER-positive and ER-negative samples randomly drawn from the
composition with respect to ER for no, standard and subgroup-specific gen43.8% tumors were assigned to luminal subtypes (18.8%
(9/48) LumA and 25% (12/48) LumB). In contrast, our
method produced 81.2% luminal subtypes, consisting of
47.9% (23/48) LumA and 33.3% LumB (16/48) (Table 2).
On the TNBC-TCGA subgroup, we expected the ma-
jority of tumors would be basal-like. Subgroup-specific
centering of the TNBC set on the triple-negative percen-
tiles (Additional file 1: Table S1 and Additional file 5:
Figure S2) resulted in 63 of the 77 TNBC tumors being
classified as basal-like (82%), and the remainder were 6
HER2-enriched, 3 LumA, 3 LumB and 2 normal-like
samples. With standard gene centering, only 36% were
classified as the basal-like subtype (Table 2). The PAM50
subtypes published in the TCGA [11], generated using the
full TCGA breast cohort, had 84% (65/77) of the cancers
classified as basal-like (Additional file 1: Table S5). Com-
pared with the published PAM50 subtypes, subgroup-edicting molecular subtypes on study cohorts with varying
ges of estrogen receptor (ER)-positive cases ranging from of 0% to
University of North Carolina set. Error rate is plotted against the
e-centering strategies.
Table 2 Comparison of gene centering with subgroup-specific strategy on the external study breast cohorts with skewed
distributiona
Prediction (%)
Dataset Feature Gene-centering method Basal-like HER2-enriched LumA LumB Normal-like
Trondheim ER-positive Standard 10 (20.8) 8 (16.7) 9 (18.8) 12 (25.0) 9 (18.8)
(n = 48) Subgroup-specific 2 (4.2) 4 (8.3) 23 (47.9) 16 (33.3) 3 (6.2)
TNBC Triple-negative Standard 28 (36.4) 9 (11.7) 19 (24.7) 12 (15.6) 9 (11.7)
(n = 77) Subgroup-specific 63 (81.8) 6 (7.8) 3 (3.9) 3 (3.9) 2 (2.6)
aER, Estrogen receptor; LumA, Luminal A; LumB, Luminal B; TNBC, Triple-negative breast cancer.
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rates of 6.5% (5/77) versus 53.2% (41/77), respectively (P <
0.0001 by McNemar test).
Discussion
Standard subtyping methods produced inaccurate classi-
fications when the clinicopathological distributions of
the study cohort did not match those of the training co-
hort. If one were to subtype a TNBC study cohort using
the PAM50 classifier, the results would be an inaccurate
representation of the PAM50 subtypes if standard gene
centering was done, because the training cohort for the
PAM50 classifier was intended to represent the general
population, not the TNBC population. Although this
problem is often overlooked, we are not the first to iden-
tify it. Others who have recognized the problem have
proposed more complex solutions, including adding or
removing samples from the study cohort to match the
clinicopathological distribution of the training cohort.
We propose a simpler solution because it does not in-
volve altering the actual samples of the study cohort.
For accurate molecular subtyping, we present an alter-
native approach to gene centering that incorporates a
routine data transformation step prior to subtyping. In
standard gene centering, gene expression values are typ-
ically expressed relative to the median (or mean). We
show that standard gene centering produces inaccurate
molecular subtype classifications when the clinicopatho-
logical distribution of the study cohort differs from that
of the training cohort. To address this issue, we propose
a new method termed subgroup-specific gene centering,
which adjusts gene expression values relative to the ex-
pression level at a specified percentile, where the per-
centile for each gene is determined from a subgroup of
the training cohort with clinicopathological characteris-
tics similar to those of the study cohort.
In comparison with standard gene centering, subgroup-
specific gene centering more accurately reproduced the in-
trinsic subtypes when applied to the five prototypic tumor
sets of the UNC cohort (Table 1 and Figure 3). Most not-
able were the accurate assignments to the luminal sub-
types, where the differences in gene expression values
defining LumA and LumB tumors are believed to be alonga continuum [17]. This correct assignment indicates that
these two types of luminal prototypic tumors in the UNC
set are likely distinct in terms of their gene expression.
Predictions on HER2-enriched prototypic tumors were
relatively less accurate than the other prototypic sets using
our method, and even less accurate using the standard
method. The increased error in this subtype is likely due
to its heterogeneous nature. On the ER-positive, ER-
negative and triple-negative subgroups of the UNC cohort,
our method produced lower classification error rates than
standard gene centering. Moreover, subtype-specific cen-
tering was consistently more accurate than standard gene
centering for study cohorts selected with varying portions
of ER-positive and ER-negative cases.
Subgroup-specific gene centering performed well on
the two external study cohorts consisting of ER-positive
and TNBC tumors, respectively. It has been reported
that ER-positive tumors tend be luminal, whereas at
least 75% of TNBC cases are basal-like [17]. Subgroup-
specific centering produced consistent findings, with
81% of the ER-positive tumors classified as luminal and
82% of the triple-negative tumors as basal-like. However,
standard gene centering produced a more uniform dis-
tribution of the tumors between the five subtypes, with
only 47% of the ER-positive tumors classified as luminal
and 36% of the triple-negative tumors as basal-like. Al-
though the information for triple-negative status is
largely missing on the UNC dataset (only ten TNBCs
available), our method outperforms the standard gene
centering on this tumor subgroup as well.
The first step underlying our method is to find a sub-
group of the training cohort that has clinicopathological
characteristics similar to those of the study cohort. We
demonstrate our method using ER status and TNBC sta-
tus as the clinicopathological characteristics. Our method
is quite flexible and can handle study cohorts composed of
a mixture of several clinically defined subgroups. For illus-
trative purposes, we constructed study cohorts with dif-
ferent mixtures of ER-positive and ER-negative cases,
because ER status is one of the major clinicopathological
markers for breast cancer and well annotated in the UNC
set. We then computed the gene-specific percentiles based
on a subgroup of the training cohort with a similar
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mix of the ER-positive and ER-negative samples). Admit-
tedly, this approach introduces some randomness because
it involves sampling the corresponding mixture subgroups
from the UNC set; however, the randomness can be aver-
aged out by using a repeated sampling procedure. Alterna-
tively, instead of subsampling, the samples may be given
different weights based on their subgroup to match the
composition of the study cohort.
Our method is not confined to a specific expression-
profiling platform, and it does not require gathering add-
itional samples to make the study cohort match the
heterogeneity of the training cohort. In general, augment-
ing a dataset is subject to data availability and platform
compatibility between study cohort and the additional
samples. Platform differences often pose major obstacles
for extracting biologically relevant signals while effectively
removing technical biases.
Our subgroup-specific gene-centering strategy can be
applied only when there are sufficient clinicopathological
data to compare the study and training cohorts. If such
data do not exist or if the data are highly correlated and
do not capture sufficient heterogeneity to compare the
study and training cohorts, our strategy cannot be ap-
plied. That said, there is no reassurance that standard
gene centering is suitable when study and training co-
horts cannot be compared.
Subgroup-specific gene centering is not suitable for
study datasets with one patient sample, because it requires
a cohort with sufficient sample size to ensure the subtyp-
ing accuracy. This limitation is largely technology-related,
as expression measurements of microarrays are often ana-
lyzed on a relative rather than absolute scale, as well as in
a platform-dependent manner. The data augmentation
strategy by merging the single sample with a sizable co-
hort from a compatible platform is one solution under the
current expression-based molecular subtyping. Alterna-
tively, one can turn to techniques such as quantitative
RT-PCR, which has technical advantages in terms of re-
producibility and quantitative assessments [6,18,19].
Subgroup-specific gene centering has capability for im-
mediate use for classifying molecular subtypes of breast
cancer, which commonly include the intrinsic signature
[1-3], PAM50 [6] and its extension to the claudin-low sub-
type [20]. In this article, we do not discuss the METABRIC
study [10], because that study did not explicitly report a
classifier (for example, centroids).
Conclusions
Compared with standard gene centering, subgroup-
specific gene centering enables more accurate molecular
subtyping in a study cohort whose clinicopathological
distribution does not match the training cohort. We dem-
onstrate subgroup-specific gene centering the PAM50breast cancer classifier, but emphasize that the subgroup-
specific gene-centering approach is applicable to any clas-
sification based on gene-centered signatures. Moreover, it
is not limited to breast cancer and can be applied to any
tissue subtyping strategy reliant on a gene centering. It
can also be applied to any characteristics for defining the
subgroups, even mutational status, provided these are
known in the training cohort.Additional files
Additional file 1: Table S1. Clinicopathological and molecular
characteristics of UNC set (n = 232). Table S2. Subtype prediction by
different strategies on UNC ER-positive subset (n = 107). Table S3.
Subtype prediction by different strategies on UNC ER-negative subset
(n = 71). Table S4. Subtype prediction by different strategies on UNC TN
subset (n = 10). Table S5. Subtype prediction by different strategies on
TCGA triple-negative subgroup (TNBC set; n = 77) compared with the
published subtype calls on TCGA cohort. Table S6. PAM50 subgroup-
specific gene centering baseline value for a few standard subgroups for
breast tumors, computed using the UNC training set.
Additional file 2: Figure S1. Subgroup-specific strategy for molecular
subtype assignment in an ER-positive study cohort (Trondheim set)
demonstrated for a single gene, ESR1. (A) Computing probe-wise
subgroup percentiles. On the training cohort (UNC set), the global
median (indicated by the gray dashed line) is mapped onto the distribution
of ER-positive subgroup, and the corresponding percentile (20%) is the
ER-positive-specific percentile used to adjust the expression of the gene
ESR1 in the study cohort. (B) Probe-wise transformation using subgroup-
specific gene centering. On an external ER-positive study cohort (Trondheim
set), instead of centering the gene value on the median of the study cohort,
which is 3.34, as indicated by the red vertical dotted line), we center the
gene ESR1 around the 20th percentile of its distribution in the study cohort,
which is 1.3.
Additional file 3: Supplementary methods. Molecular subtyping for
clinically defined breast cancer subgroups.
Additional file 4: Figure S3. Subtyping accuracy versus subgroup
sample size of UNC basal prototypical subgroup. The horizontal axis
denotes the sample size of data from downsampling UNC basal
prototypical subgroup (from 57 to 1). The vertical axis shows the
subtyping prediction accuracy using our subgroup-specific gene centering
method. The accuracy is calculated based on the percentage of the
predicted basal subtype on the corresponding dataset. Individual predictions
are shown as circles, and a Loess smooth line (span 0.75) is fitted on the
prediction points. Two hundred rounds of downsampling were performed.
The color of the lines reflects the statistical confidence in the regression
estimation.
Additional file 5: Figure S2. Subgroup-specific strategy for molecular
subtype assignment in a triple-negative breast cancer study cohort for
the expression of gene SLC39A6. (A) Computing probe-wise subgroup
percentiles. On the training cohort (UNC set), the global median of the
UNC set (indicated by the white dashed line) is mapped onto the distribution
of the TN subgroup, and the corresponding percentile (100%) is the
TN-specific percentile for gene SLC39A6. (B) Probe-wise transformation using
subgroup-specific percentile. On an external TNBC study cohort (TNBC set),
instead of centering on the median of the study cohort (−1.46), we centered
the distribution of gene SLC39A6 on the 100% percentile of the TN
distribution of the study cohort (3.98).Abbreviations
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UNC: University of North Carolina.
Zhao et al. Breast Cancer Research  (2015) 17:29 Page 9 of 9Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XZ, EAR, RT and SP conceived and designed the study. XZ performed
experiments and analysis. XZ, EAR, RT and SP analyzed and interpreted the
results. XZ, EAR and SP wrote the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
This study was supported by National Institutes of Health grants 1U01
CA154969 and 1U54 CA149145. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript. The Trondheim dataset was obtained from the Sørlie group in
Oslo University Hospital and the Bathen group in The Norwegian University
of Science and Technology.
Author details
1Center for Cancer Systems Biology, Stanford University, James H. Clark
Center 318 Campus Drive, Stanford, CA 94035-5442, USA. 2Department of
Radiology, School of Medicine, Stanford University, James H. Clark Center,
Room S255, 318 Campus Drive, Stanford, CA 94305-5442, USA. 3Department
of Tumor Biology, Institute for Cancer Research, The Norwegian Radium
Hospital, Oslo University Hospital, Oslo 0424, Norway. 4Departments of
Health, Research & Policy, and Statistics, Stanford University, Redwood
Building, Room T101C, 150 Governor's Lane, Stanford, CA 94305, USA.
Received: 27 February 2014 Accepted: 19 January 2015
References
1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.
Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene
expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.
3. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated
observation of breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci U S A. 2003;100:8418–23.
4. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular
portraits of breast tumors are conserved across microarray platforms. BMC
Genomics. 2006;7:96.
5. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, et al.
Classification and risk stratification of invasive breast carcinomas using a
real-time quantitative RT-PCR assay. Breast Cancer Res. 2006;8:R23.
6. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al.
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin
Oncol. 2009;27:1160–7.
7. Prat A, Perou CM. Mammary development meets cancer genomics. Nat
Med. 2009;15:842–4.
8. Russnes HG, Navin N, Hicks J, Børresen-Dale AL. Insight into the
heterogeneity of breast cancer through next-generation sequencing. J Clin
Invest. 2011;121:3810–8.
9. Sørlie T, Borgan E, Myhre S, Vollan HK, Russnes H, Zhao X, et al. The
importance of gene-centring microarray data. Lancet Oncol. 2010;11:719–21.
10. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda O, Dunning M, et al. The
genomic and transcriptomic architecture of 2,000 breast tumours reveals
novel subgroups. Nature. 2012;486:346–52.
11. The Cancer Genome Atlas Network. Comprehensive molecular portraits of
human breast tumours. Nature. 2012;490:61–70.
12. Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of
systematic microarray data biases. Bioinformatics. 2004;20:105–14.
13. Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, et al.
Merging transcriptomics and metabolomics – advances in breast cancer
profiling. BMC Cancer. 2010;10:628.
14. R Development Core Team. R: a language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
http://www.R-project.org/. ISBN 3-900051-07-0.
15. Stanford Center for Cancer Systems Biology. Data integration core. Stanford
Medicine. http://ccsb.stanford.edu/research/core.html. Accessed 3 Mar 2015.16. National Cancer Institute, National Human Genome Research Institute. The
Cancer Genome Atlas. Bethesda, MD: National Institutes of Health.
http://cancergenome.nih.gov/. Accessed 3 Mar 2015.
17. Perou CM, Børresen-Dale AL. Systems biology and genomics of breast
cancer. Cold Spring Harb Perspect Biol. 2011;3:a003293.
18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to
predict recurrence of tamoxifen-treated, node-negative breast cancer.
N Engl J Med. 2004;351:2817–26.
19. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new
molecular predictor of distant recurrence in ER-positive, HER2-negative
breast cancer adds independent information to conventional clinical risk
factors. Clin Cancer Res. 2011;17:6012–20.
20. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer.
Mol Oncol. 2011;5:5–23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
